Shaily Engineering Plastics profit surges 46%, healthcare revenue jumps 85%
Shaily Engineering Plastics posted strong Q1FY27 results with standalone PAT up 46% to ₹52.47 crore and consolidated revenue rising 14% to ₹280.7 crore. Healthcare revenue surged 85% due to new drug delivery device projects, offsetting a 24% decline in the consumer segment. Operational efficiency improved with EBITDA margins expanding 120 bps to 29.7%.

*this image is generated using AI for illustrative purposes only.
Shaily Engineering Plastics delivered a robust financial performance in Q1FY27, with standalone net profit after tax (PAT) surging 46% year-on-year to ₹52.47 crore. The strong bottom-line growth was underpinned by an 85% surge in healthcare segment revenue to ₹142.4 crore, which offset a 24% decline in consumer demand. Consolidated EBITDA margins expanded by 120 basis points (bps) to 29.7%, reflecting improved operational efficiency and higher machine utilization across its Gujarat facilities.
The Board of Directors approved the unaudited financial results on August 08, 2026, in compliance with Regulation 33 of the SEBI Listing Regulations, 2015. Statutory auditors B S R and Co. issued an unmodified limited review report. The company also released its Q1 & FY27 Investor Presentation, highlighting new business confirmations in semaglutide pens supply for Canada and Brazil, as well as projects from FMCG and automotive clients.
Financial Performance Highlights
Consolidated revenue from operations rose 14% YoY to ₹280.7 crore. While standalone PAT jumped 46%, consolidated PAT grew 17% to ₹48.0 crore, indicating that subsidiary performance diluted the overall growth rate slightly. Cash PAT, defined as PAT plus depreciation, increased 18% to ₹62.1 crore.
| Metric | Standalone Q1FY27 | Standalone Q1FY26 | Change | Consolidated Q1FY27 | Consolidated Q1FY26 | Change |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹274.78 cr | ₹225.10 cr | +22% | ₹280.7 cr | ₹246.7 cr | +14% |
| Net Profit After Tax | ₹52.47 cr | ₹35.97 cr | +46% | ₹48.0 cr | ₹41.1 cr | +17% |
| EBITDA Margin | — | — | — | 29.7% | 28.5% | +120 bps |
| Gross Profit Margin | — | — | — | 56.6% | 51.2% | +540 bps |
Segment-Wise Revenue Breakdown
The healthcare segment emerged as the primary growth driver, with revenue rising 85% to ₹142.4 crore from ₹77.2 crore in Q1FY26. This growth was fueled by customer approvals for semaglutide pen supplies and two new IP-led platform projects. Conversely, the consumer segment faced weaker market demand in Europe and the USA, leading to a 24% revenue drop to ₹115.5 crore. The industrial segment grew 25% to ₹22.7 crore, supported by new projects in appliances, consumer electronics, and automotive components.
What the Numbers Show
The divergence between standalone and consolidated profitability highlights the impact of subsidiary operations. While the parent entity achieved a 46% PAT surge, consolidated PAT grew only 17%. This suggests that subsidiaries, including Shaily Innovations Ltd and Shaily Innovations FZCO, contributed less proportionally to bottom-line growth. Notably, one subsidiary reported a net loss of ₹1.97 crore, which was deemed immaterial but diluted aggregate profit expansion. However, the group’s overall health remains strong, with Return on Capital Employed (RoCE) improving by 320 bps to 39.0% and Total Debt/Equity ratio decreasing from 0.3 to 0.2.
Historical Stock Returns for Shaily Engineering Plastics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.06% | +4.40% | +9.98% | +57.32% | +91.01% | +683.33% |
How will the new semaglutide pen supply contracts in Canada and Brazil impact Shaily's revenue mix and margin profile over the next 12-18 months?
What specific strategies is management implementing to reverse the 24% decline in the consumer segment amid weakening demand in Europe and the USA?
Will the improved operational efficiency and machine utilization at Gujarat facilities be sustainable as the company scales up production for new healthcare projects?


































